Pillar Clinical Research, LLC

Running trials

• Recruiting

  A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

  NCT07734493· Phase 1· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

  NCT07565428· Phase 3· Source

• Recruiting

  A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

  NCT07615426· Phase 1· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia3 recruiting
• Depression1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Source

• Completed

  A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

  NCT05848700· Phase 1· Source

• Completed

  A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

  NCT05628103· Phase 3· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Source

• Completed

  A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

  NCT04937829· Phase 1· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Source